Hyperbaric Oxygen for Tinnitus: Where the Line Actually Is

Hyperbaric oxygen therapy is a real medical treatment with a real, narrow role in ear medicine — and that role is not tinnitus. The distinction between where it works and where it is sold is unusually sharp here, and unusually easy to state.

The one sentence that settles it

The Cochrane review on hyperbaric oxygen for sudden hearing loss and tinnitus ends with this:

There is no evidence of a beneficial effect of HBOT on chronic ISSHL or tinnitus and we do not recommend the use of HBOT for this purpose.

That is a systematic review of the exact question, reaching a direct recommendation against. Very little in tinnitus is stated that plainly.

Where the evidence does point somewhere

The same review found something for a different condition, and the difference is what matters.

For acute idiopathic sudden sensorineural hearing loss — the time-critical emergency covered in its own article — seven trials with 392 participants produced a real but qualified signal. HBOT did not significantly improve the chance of a 50% recovery in hearing threshold (risk ratio 1.53, 95% CI 0.85 to 2.78). It did improve the chance of a 25% recovery (risk ratio 1.39, 95% CI 1.05 to 1.84), a 22% greater chance of improvement, with a number needed to treat of 5. Average pure-tone threshold came out 15.6 dB better.

Three caveats travel with those numbers, and the reviewers state all three: the studies were small and generally of poor quality, the clinical significance of the improvement remains unclear, and an appropriately powered trial is still justified to work out which patients, if any, benefit most.

And on tinnitus specifically, even within those acute trials: the significance of any improvement in tinnitus could not be assessed by pooled analysis. Not "no effect" — no analysable data.

What the guideline permits, exactly

The American Academy of Otolaryngology–Head and Neck Surgery's sudden hearing loss guideline places HBOT among its options — the weakest of its three tiers, below recommendations — in two specific circumstances:

• Combined with steroid therapy, within two weeks of the onset of sudden sensorineural hearing loss.
• Combined with steroid therapy as salvage therapy, within one month of onset.

Read the shape of that rather than just the permission. It is bounded by a condition (sudden hearing loss, not tinnitus), a companion treatment (steroids, not HBOT alone), and a clock (two weeks, or one month for salvage). Chronic tinnitus fails all three tests.

The same guideline makes a strong recommendation that patients left with residual hearing loss or tinnitus be counselled about audiologic rehabilitation and supportive measures — which is where someone in that position is actually meant to be directed.

Why this gets sold anyway

The mechanism is genuinely plausible, which is the usual reason a treatment outlives its evidence. HBOT raises dissolved oxygen in the blood, the cochlea has a demanding blood supply with no backup circulation, and a treatment that improves oxygen delivery to the inner ear is a reasonable thing to try. The Cochrane review opens with exactly that rationale.

Plausible mechanism and demonstrated benefit are different things, and this site's ginkgo, PEMF and laser therapy articles each describe a version of the same gap.

What is unusual here is that the plausible mechanism did produce a signal — in the acute condition, under a clock. The marketing keeps the signal and drops the conditions.

What to actually do

• If your hearing dropped suddenly, within the last two weeks, HBOT is a legitimate conversation to have — alongside steroids, not instead of them, and after reading what sudden hearing loss actually requires, because the timing there is the whole thing.
• If your tinnitus is chronic, there is nothing here for you, and the review says so directly rather than leaving it to inference.
• If a clinic offers HBOT for tinnitus, the question that sorts it is which condition and when it started. Courses run to dozens of sessions, are rarely covered for tinnitus, and the ear barotrauma that pressurised treatment can cause is a notable risk to accept for an ear complaint with no expected benefit.